Dr. Jennifer Marks, MD breaks down latest data for Trastuzumab Deruxtecan in HER2-overexpressing solid tumors including NSCLC at #LungCancerSymposium . Rapidly evolving space & need more prospective data to ID pts most likely to respond such as concurrent HER2 amp. Georgetown Lombardi

My colleague Dr. Michael Conroy from Johns Hopkins Thoracic Oncology discussing #KN671 in addition to other neoadjuvant/perioperative studies at the #LungCancerSymposium with the #CancerSupportCommunity ! #nsclc #lcsm Susan Combs Scott, MD Joshua Reuss

Will use a step up dosing approach and requires monitoring for 24h after the 1st and 2nd infusions. Pts should stay close to a hospital for 48h after the 1st and 2nd infusions - to monitor for cytokine release and ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome).

Outcomes with first-line osimertinib in 37 pts with rare atypical #EGFR exon 19 or compound mutations in #JTOCRR JTO & JTO CRR from Dr. Susan Combs Scott, MD Tia Cheunkarndee. RR 76%, median PFS 13m, time to discontinuation 22m, mOS 36m.
jtocrr.org/article/S2666-…

Now NEJM from Dr. Tina Cascone et al - phase 3 CheckMate 77T results: addition of neoadjuvant plus adjuvant nivolumab to neoadjuvant chemo in pts with resectable NSCLC improves pCR (25.3% to 4.7%) and EFS (HR 0.58) with no new safety signals.

nejm.org/doi/full/10.10…

Join us for an insightful discussion on evolving therapies in NSCLC led by 🌟 fellows Jennifer Marks, MD and Michael Conroy at the #LungCancerSymposiun tmrw 5/16 at Joe Theisman's Restaurant & Bar. Georgetown Lombardi Johns Hopkins Thoracic Oncology Susan Combs Scott, MD Georgetown Hematology/Oncology Fellowship

Congratulations to John Marshall on being named a 2024 Giants of Cancer Care® Inductee. This program honors and celebrates the accomplishments of leading researchers and educators whose discoveries have propelled the field and set the groundwork for future advancements. OncLive.com

Congratulations to the newly appointed ASCO Committee leaders!
NiharikaDixit, Health Policy Committee
Sam Brondfield, MD, MAEd, Education Council
Dr. Jo Chien, AM Scientific Program Committee
Joshua Reuss, Membership Advisory Committee
Steve Lee, Coverage & Reimbursement Steering Group

So many terrific folks leading ASCO committees! Congrats to Erika Ruiz-Garcia, Mina S. Sedrak, Jane Lowe Meisel, MD, Joshua Reuss, Ashley Love Sumrall, MD, FACP, FASCO & the many other #oncology superstars on this list who will be taking the organization to new heights!

If you’re in the DMV area, the lovely Dr. Michael Conroy and I will be discussing updates in #NSCLC on May 16th! RSVP using the following link: cancersupportcommunity.salsalabs.org/lung-cancer-sy… . The fabulous thoracic experts, Drs. Susan Combs Scott, MD and Joshua Reuss, will be in attendance as well! #lcsm

These wonderful people 🤠🫁🩺 #TexasLung24 TLC Conference Brendon Stiles @esinghimd Dr. Estela Rodriguez Stephen V Liu, MD Joshua Reuss Narjust Florez, MD, FASCO Dr. Julie Brahmer Misty Dawn Shields Christine Lovly, MD, PhD Jason Porter Christian Rolfo Tigirlily Gold

Tigirlily Gold closing out #TexasLung24 with awesome 🎶 + a message of service through Musicians On Call. Service to patients should remain our “north star” 🌟 - the reason we join together at conferences. #TexasLung24 friends - please consider supporting :
musiciansoncall.org

Find yourself a mentor who dances with you and don’t let go. #SheforShe #WomeninThoracicOncology #lcsm #TexasLung24 Susan Combs Scott, MD Dr. Julie Brahmer Sidney Kimmel Cancer Center – Jefferson Health Hematology & Oncology Women Physicians Group—HOWPG #mentoringmatters

Immunotherapy grandmaster, mentor and friend Dr. Dr. Julie Brahmer discusses trial endpoints in IO clinical trials in NSCLC at #TexasLung24 including surrogate endpoints for survival. Can we use pathologic response outcomes to guide Rx decision-making? More and mature data needed.

Dr. Brendon Stiles takes us into the mind of a thoracic surgeon discussing surgical dogma in NSCLC at #TexasLung24 . Interesting to see how this conversation has evolved concurrent with systemic therapy advances.

Dr. Jamie Chaft sets the stage for 'debating with the stars' with a thought-provoking discussion on role of adjuvant therapy after neoadj therapy in resectable NSCLC at #TexasLung24 .

#TexasLung24 Joshua Reuss Georgetown Lombardi assembles all the ADCs (avengers) in lung cancer

➡️tumor agnostic HER2 ADCs (T-DXd) w ⬆️CNS activity
➡️challenging targets (anti-TROP2)
➡️new AEs to manage (ILD)
➡️Next generation of ADCs emerging. IASLC #lcsm

A treat to hear IASLC Karen Kelly speak on perioperative chemo-IO in resectable NSCLC at #TexasLung24 . Who warrants perioperative vs neoadjuvant alone? PD-L1-? Non-path CR? Hopefully we will see trials in this space to address this.

Neoadjuvant pioneer, friend and mentor Patrick Forde presenting on neoadjuvant IO in resectable NSCLC at #TexasLung24 . Impressive how a short duration of therapy can lead to improved longterm outcomes and cure!

Always enjoy hearing donington speak, today discussing surgical evaluation and adjuvant IO therapy in resectable NSCLC at #TexasLung24 . From the mouth of a surgeon - surgery alone doesn't cure the majority of pts! Need systemic therapy to enhance chances of cure!